CAM
KPTI icon

ClariVest Asset Management’s Karyopharm Therapeutics KPTI Stock Holding History

ClariVest Asset Management’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-3,973
Closed -$440K – 725
2022
Q1 		$440K Buy
+3,973
New +$495K 0.02% 405

Other funds holding KPTI

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

ClariVest Asset Management's KPTI Position: Q2 2022 in Review

ClariVest Asset Management sold out of Karyopharm Therapeutics (KPTI) in Q2 2022, closing a stake of 3,973 shares — an estimated $440K sold.

ClariVest Asset Management first reported a position in KPTI in Q1 2022 and held it in 1 quarter. The position peaked at $440K in Q1 2022. 149 funds tracked by Wall St. Rank hold KPTI as of Q2 2022.

  • ClariVest Asset Management reported no remaining Karyopharm Therapeutics position as of Q2 2022 after selling out during the quarter.
  • ClariVest Asset Management sold 3,973 Karyopharm Therapeutics shares in Q2 2022, an estimated $440K.
  • ClariVest Asset Management first reported a position in Karyopharm Therapeutics in Q1 2022 and held it in 1 quarter.
  • ClariVest Asset Management's Karyopharm Therapeutics position peaked at $440K in Q1 2022.
  • 149 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2022.

Based on ClariVest Asset Management's 13F filing for Q2 2022, filed 12 Aug 2022.